Cart
sales@molnova.com
GSK1838705A
CAS No. 1116235-97-2
GSK1838705A( GSK 1838705A | GSK-1838705A )
Catalog No. M10424 CAS No. 1116235-97-2
GSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 120 | In Stock |
|
| 25MG | 252 | In Stock |
|
| 50MG | 455 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK1838705A
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM.
-
DescriptionGSK1838705A is a potent, specific inhibitor of IGF-IR and insulin receptor (IR) with IC50 of 2.0 and 1.6 nM, also is a potent inhibitor of ALK with IC50 of 0.5 nM; display excellent kinase selectivity on a panel of 224 unique protein kinases with only 7 additional kinases to be inhibited by >50% at 0.3 uM; inhibits a panel of cell lines derived from solid and hematologic tumors with IC50 of 20 nM-8 uM (NCI-H929 IC50=197 nM); causes complete regression of ALK-dependent tumors, retards the growth of human tumor xenografts in vivo with minimal effects on glucose homeostasis.
-
In Vitro——
-
In Vivo——
-
SynonymsGSK 1838705A | GSK-1838705A
-
PathwayAngiogenesis
-
TargetALK
-
RecptorALK|IGF-1R|InsulinReceptor|JNK3|RSK1
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1116235-97-2
-
Formula Weight532.5693
-
Molecular FormulaC27H29FN8O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NC)C1=C(F)C=CC=C1NC2=C3C(NC=C3)=NC(NC4=CC5=C(C=C4OC)CCN5C(CN(C)C)=O)=N2
-
Chemical NameBenzamide, 2-[[2-[[1-[2-(dimethylamino)acetyl]-2,3-dihydro-5-methoxy-1H-indol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sabbatini P, et al. Mol Cancer Ther. 2009 Oct;8(10):2811-20.
2. Zhou F, et al. Onco Targets Ther. 2015 Apr 10;8:753-60.
3. Refolo MG, et al. Oncotarget. 2017 Sep 30;8(61):103465-103476.
4. Kelleher FC, et al. Eur J Cancer. 2010 Sep;46(13):2357-68.
molnova catalog
related products
-
LDK378 dihydrochlori...
Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50 values of 8, 7, and 23 nM, respectively).
-
Iruplinalkib
Iruplinalkib (WX-0593) is an orally active, selective and potent ALK and ROS1 tyrosine kinase inhibitor with anticancer activity for use in the study of non-small cell lung cancer.
-
SB-505124 hydrochlor...
SB-505124 hydrochloride (SB505124 hydrochloride) is an orally available, selective and potent inhibitor of TGF-β type I receptors (ALK4, ALK5, ALK7) with IC50 values of 129 nM and 47 nM for ALK4 and ALK5, respectively.
